CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 78 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Liposomal bupivacaine 20mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04003987
NCT04003987Phase 3Completed
CompareCT.gov

Erector Spinae Plane Block Versus Transverse Abdominis Plane Block in Laparoscopic Hysterectomy

Indiana University·interventional·Posted Jul 1, 2019·Updated Jul 5, 2022

In Brief

A Phase 3 clinical trial evaluating Liposomal bupivacaine and bupivacaine, 0.125% for Hysterectomy. Completed, enrolled 78 participants across 2 sites.

Detailed Summary

The purpose of this study is to compare the difference between two different pain control methods in patients who will be having a hysterectomy surgery. By collecting this data, we aim to show improved postoperative pain scores, decreased opioid needs, and decreased opioid side effects (nausea, sedation, ileus, urinary retention, respiratory depression).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHysterectomy
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 1, 2019
Enrollment StartMay 1, 2019
Primary CompletionMar 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.0 years ago

Interventions

Liposomal bupivacainedrug

20ml

bupivacaine, 0.125%drug

60ml